The Claim

GLP-1 receptor agonists, such as Exenatide and Dulaglutide, may be associated with reduced substance use disorders, particularly for alcohol and nicotine, in human participants across multiple clinical studies, indicating a potential therapeutic role in addiction treatment.

Source: Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
20score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

Some diabetes drugs like Exenatide and Dulaglutide might help people cut down on drinking alcohol or smoking, based on several medical studies.

See the scientific wording

GLP-1 receptor agonists, including Exenatide and Dulaglutide, may be associated with a reduction in substance use disorders, particularly for alcohol and nicotine, in human participants across multiple clinical studies, suggesting a potential role in addiction treatment.

What the research says

1 study

  1. Study: Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.

    The study looked at drugs like Exenatide and Dulaglutide in people and found they may help reduce alcohol and nicotine use, which supports the idea that these drugs could help treat addiction.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.